Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer
Recurrent Non Small Cell Lung Cancer

Interventions

DRUG: Etirinotecan pegol (NKTR-102)

Sponsor

Abramson Cancer Center at Penn Medicine